Evergreen Capital Management LLC Has $522,000 Stake in Sanofi (NASDAQ:SNY)

Evergreen Capital Management LLC cut its holdings in shares of Sanofi (NASDAQ:SNY) by 16.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,768 shares of the company’s stock after selling 2,068 shares during the quarter. Evergreen Capital Management LLC’s holdings in Sanofi were worth $522,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares during the period. Magnetar Financial LLC grew its holdings in Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after buying an additional 2,306,286 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after buying an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD boosted its position in shares of Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of Sanofi in the fourth quarter valued at about $51,520,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ SNY opened at $56.65 on Thursday. The firm’s 50 day simple moving average is $54.77 and its 200 day simple moving average is $50.70. The firm has a market capitalization of $143.48 billion, a price-to-earnings ratio of 28.47, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same quarter last year, the company posted $0.95 EPS. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, research analysts expect that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.